Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 91

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

CXCR3 Depleting Antibodies Prevent and Reverse Vitiligo in Mice

Richmond, Jillian M., Masterjohn, Elizabeth, Chu, Ruiyin, Tedstone, Jennifer, Youd, Michele E., Harris, John E.·2017·Journal of Investigative Dermatology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jid.2016.10.048

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 20

  1. Agarwal, 2015, Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo, J Invest Dermatol, 135, 1080, 10.1038/jid.2014.529 · DOI
  2. Anolik, 2005, New treatments for SLE: cell-depleting and anti-cytokine therapies, Best Pract Res Clin Rheumatol, 19, 859, 10.1016/j.berh.2005.05.006 · DOI
  3. Bertolotti, 2014, Type I interferon signature in the initiation of the immune response in vitiligo, Pigment Cell Melanoma Res, 27, 398, 10.1111/pcmr.12219 · DOI · Paper page
  4. Coles, 2008, Alemtuzumab vs. interferon beta-1a in early multiple sclerosis, N Engl J Med, 359, 1786, 10.1056/NEJMoa0802670 · DOI · Paper page
  5. Coppieters, 2013, Functional redundancy of CXCR3/CXCL10 signaling in the recruitment of diabetogenic cytotoxic T lymphocytes to pancreatic islets in a virally induced autoimmune diabetes model, Diabetes, 62, 2492, 10.2337/db12-1370 · DOI
  6. Fife, 2001, CXCL10 (IFN-gamma-inducible protein-10) control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis, J Immunol, 166, 7617, 10.4049/jimmunol.166.12.7617 · DOI · Paper page
  7. Harris, 2012, A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin, J Invest Dermatol, 132, 1869, 10.1038/jid.2011.463 · DOI · Paper page
  8. Klein, 2004, IFN-inducible protein 10/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis, J Immunol, 172, 550, 10.4049/jimmunol.172.1.550 · DOI
  9. Long, 2012, Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease, Gastroenterology, 143, 390, 10.1053/j.gastro.2012.05.004 · DOI · Paper page
  10. Morelli, 2003, Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production, Blood, 101, 611, 10.1182/blood-2002-06-1769 · DOI · Paper page
  11. Muller, 2007, CXCR3 signaling reduces the severity of experimental autoimmune encephalomyelitis by controlling the parenchymal distribution of effector and regulatory T cells in the central nervous system, J Immunol, 179, 2774, 10.4049/jimmunol.179.5.2774 · DOI · Paper page
  12. Overwijk, 2003, Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells, J Exp Med, 198, 569, 10.1084/jem.20030590 · DOI · Paper page
  13. Palermo, 2001, Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo, J Invest Dermatol, 117, 326, 10.1046/j.1523-1747.2001.01408.x · DOI · Paper page
  14. Paradisi, 2014, Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo, J Am Acad Dermatol, 71, 1110, 10.1016/j.jaad.2014.07.050 · DOI
  15. Rashighi, 2014, CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo, Sci Transl Med, 6, 223ra23, 10.1126/scitranslmed.3007811 · DOI · Paper page
  16. Richmond, 2013, Innate immune mechanisms in vitiligo: danger from within, Curr Opin Immunol, 25, 676, 10.1016/j.coi.2013.10.010 · DOI · Paper page
  17. Teulings, 2013, Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners, Br J Dermatol, 168, 162, 10.1111/bjd.12111 · DOI · Paper page
  18. van den Boorn, 2009, Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients, J Invest Dermatol, 129, 2220, 10.1038/jid.2009.32 · DOI · Paper page
  19. Wang, 2016, Increased expression of CXCR3 and its ligands in vitiligo patients and CXCL10 as a potential clinical marker for vitiligo, Br J Dermatol, 174, 1318, 10.1111/bjd.14416 · DOI · Paper page
  20. Yamada, 2012, Acceleration of diabetes development in CXC chemokine receptor 3 (CXCR3)-deficient NOD mice, Diabetologia, 55, 2238, 10.1007/s00125-012-2547-8 · doi:10.1007/s00125-012-2547-8

Cited by

See all 91

Metadata

Authors
Richmond, J. M., Masterjohn, E., Chu, R., Tedstone, J., Youd, M. E., & Harris, J. E.
Venue
Journal of Investigative Dermatology
Publisher
Elsevier BV
Published
2017-04
Volume
137
Issue
4
Pages
982-985
ISSN
0022-202X
Cited by
91
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CXCR3 Depleting Antibodies Prevent and Reverse Vitiligo in Mice. https://app.cochat.ai/papers/10.1016/j.jid.2016.10.048
The paper
Richmond, J. M., Masterjohn, E., Chu, R., Tedstone, J., Youd, M. E., & Harris, J. E. (2017). CXCR3 Depleting Antibodies Prevent and Reverse Vitiligo in Mice. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2016.10.048

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.